DoNotAge Conference 2026 brought together researchers working across DNA repair, epigenetics, inflammation, exercise biology, cardiovascular health, muscle ageing and experimental rejuvenation. The official DoNotAge Conference 2026 highlights page provides the event-level reference, while the individual analyses below connect each topic to the strongest supporting scientific source available.
View the official DoNotAge Conference 2026 highlights →
DoNotAge Conference 2026 at a glance
- Eleven conference topics are mapped below, covering 12 named researchers and speakers.
- The evidence spans multiple levels. Some topics connect to peer-reviewed protocols or registered human trials; others remain conference-stage, preclinical or mechanistic.
- Several talks connect to documented DoNotAge-supported research. These include NUS PROMETHEUS, the UCLan quercetin trial, the 2026 BSRA grants, the ICR–Unicamp rejuvenation replication programme and Constanza Cortes’ PS18 aged-mouse study.
Speakers, topics and evidence status
| Speaker | Main topic | Evidence status | Analysis |
|---|---|---|---|
| Vera Gorbunova | SIRT6, DNA repair, epigenetic ageing and fucoidan | Published research plus conference-stage material | SIRT6 lecture analysis |
| Andrei Seluanov | Inflammaging, LINE-1 and the dark genome | Published preclinical research plus conference-stage material | LINE-1 analysis |
| Søren Wilton Kudahl-Laursen | Spermidine and muscle stem-cell proliferation | Conference-stage | Spermidine analysis |
| Nicolás Cherñavsky | Rejuvenation replication and young-plasma-derived material | Ongoing preclinical replication | Replication analysis |
| Joanna Ward | Inflammaging, ASCVD and NLRP3 | Conference-stage plus documented research grant | Joanna Ward analysis |
| Sergej M. Ostojic | Creatine, bioenergetics and healthy ageing | Conference-stage discussion with broader published literature | Creatine analysis |
| Ciara Angeli Juan | Exercise, SIRT1, quercetin and DNA damage | Conference-stage plus preprint-stage research | Quercetin and DNA-damage analysis |
| Constanza Cortes | PS18, prosaposin, exerkines and the exercise-mimetic hypothesis | Primary conference lecture plus published preclinical research; new aged-mouse study prospective | PS18 analysis |
| Lindsay Bottoms & Jonathan Sinclair | Quercetin, blood pressure and cardiometabolic outcomes | Conference-stage result plus registered randomized human trial | Blood-pressure analysis |
| David Weinkove | Why ageing clinical trials are difficult | Research-methodology conference discussion | Trial-methodology analysis |
| Rebecca Sumner | CDK4/6, cell division and inflammatory regulation | Conference-stage mechanistic research | CDK4/6 analysis |
Five major research connections from the conference
1. NUS PROMETHEUS
A 2026 GeroScience protocol describes a multimodal healthy-ageing intervention that includes 2.4 g/day of DoNotAge SIRT6Activator. The paper states that DoNotAge supplied SIRT6Activator, while the study funding comes from the XPRIZE Foundation and the National University of Singapore. Because PROMETHEUS is multimodal, whole-program outcomes cannot be attributed to one component.
2. UCLan quercetin trial NCT06230861
ClinicalTrials.gov lists DoNotAge.org as a collaborator on NCT06230861, a University of Central Lancashire randomized, double-masked quercetin study focused on cardiometabolic outcomes including systolic blood pressure. The registry establishes the collaboration and design; it does not establish a positive result.
3. The 2026 BSRA small research grants
The British Society for Research on Ageing says DoNotAge.org funded 15 of the 18 small research grants awarded across 13 UK institutions in its 2026 round, including Joanna Ward’s work at the University of Lincoln on cardiovascular disease, inflammation and ageing.
4. ICR–Unicamp rejuvenation replication
The Rejuvenation Science Institute reports that DoNotAge contributed US$25,000 to an experimental ICR–Unicamp rat rejuvenation replication programme. The programme remains preclinical, and its August 2026 update reported that the March grip-strength result had not been replicated.
Read the funding and replication analysis.
5. The DoNotAge-funded PS18 aged-mouse study
Constanza Cortes presented an eight-week aged-mouse experiment funded by DoNotAge that will compare sedentary vehicle control, sedentary PS18 treatment and treadmill exercise. Planned outcomes include frailty or healthspan measures, cognition, metabolic health, body composition and tissue-level analyses.
PS18 is an 18-amino-acid peptide derived from prosaposin. Published mouse work supports further investigation of this pathway, but the broader premise that prosaposin itself is consistently exercise responsive remains contested in the 2026 literature.
Read the PS18 and exercise-mimetic analysis.
How to interpret conference evidence
| Evidence label | What it can establish | What it cannot establish by itself |
|---|---|---|
| Peer-reviewed protocol | A formally published study design and planned intervention | That the intervention produced a positive outcome |
| Registered human trial | Prospectively registered design, outcomes and study status | Positive efficacy before results are reported |
| Funded research project | A documented funding relationship and research objective | That the project has already succeeded |
| Preclinical research | Mechanistic or animal evidence worth investigating further | Equivalent effects in humans |
| Conference-stage claim | What a researcher presented or discussed at the event | Automatic peer review, replication or clinical validation |
Primary conference sources
- Official DoNotAge Conference 2026 highlights
- Conference lecture video used for the Vera Gorbunova and Andrei Seluanov analyses
- Constanza Cortes lecture: PS18, prosaposin and the exercise-mimetic project
- DoNotAge research, trials and grants tracker
- DoNotAge scientists and research network
DoNotAge Conference 2026 FAQ
Where can I see the official conference highlights?
DoNotAge publishes a dedicated Conference 2026 highlights page. The individual analyses in this archive add publication, registry and institutional context to the conference topics.
Was all research presented at the conference peer reviewed?
No. The event spans multiple evidence states. Some themes connect to peer-reviewed papers or protocols, some to registered human trials, and others to preclinical, mechanistic or conference-stage material.
What is the PS18 study presented by Constanza Cortes?
It is a DoNotAge-funded prospective preclinical study in aged mice. Over eight weeks, researchers plan to compare sedentary vehicle control, sedentary PS18 treatment and treadmill exercise. No human efficacy conclusion follows from this design.
Which DoNotAge-related human studies connect to the conference?
Two especially important connections are NUS PROMETHEUS, whose peer-reviewed multimodal protocol includes DoNotAge-supplied SIRT6Activator, and UCLan trial NCT06230861, which lists DoNotAge.org as a collaborator on a randomized quercetin study.
Where can I find every lecture analysis?
Use the DoNotAge Conferences archive for all published conference analyses, or return to the DoNotAge Intelligence Center for research, scientists, news and practical company guidance.
Linked entities and research
DoNotAge Conference 2026
DoNotAge Conference 2026 was held in London on September 26–27, 2026. The official highlights archive presents 12 2026 conversations spanning human trials, DNA repair, inflammation, muscle and exercise, replication and research funding, plus a 2025 conference recap.
DoNotAge-Funded PS18 Exercise-Mimetic Study in Aged Mice
DoNotAge funded the aged-mouse experimental step presented by Constanza Cortes at DoNotAge Conference 2026. The project tests the prosaposin-derived peptide PS18 against sedentary control and treadmill exercise; it is not a human trial.
DoNotAge.org–BSRA Small Research Grants 2026 — 15 Awards
BSRA announced 18 Small Research Grants across 13 UK institutions in 2026. Alan Graves stated that DoNotAge.org funded 15 of those projects; Quest NutraPharma also sponsored the programme.
Joanna Ward — Cardiovascular Disease and Inflammation in Ageing
BSRA identifies Joanna Ward as a recipient of a DoNotAge.org-BSRA Small Research Grant in 2026.
PROMETHEUS Clinical Trial Protocol: Tailoring Healthy Ageing with Lifestyle and Nutraceuticals
The published protocol states that DoNotAge.org provided SIRT6Activator used in the study. The study is funded by the XPRIZE Foundation and National University of Singapore.
Effects of Quercetin Supplementation on Cardiometabolic Parameters — NCT06230861
ClinicalTrials.gov lists DoNotAge.org as a collaborator; the University of Central Lancashire is the sponsor.
ICR–Unicamp Rat Rejuvenation Replication Experiment
ICR states that DoNotAge.org committed US$25,000 toward the rat rejuvenation experiment and describes DoNotAge.org as a project partner.
Vera Gorbunova
Speaker at DoNotAge Conference 2026.
Andrei Seluanov
Speaker at DoNotAge Conference 2026.
Søren Wilton Kudahl-Laursen
DoNotAge Conference 2026 speaker. The official conference archive describes an ongoing older-adult muscle-regeneration study comparing DoNotAge Pure Spermidine with placebo; DoNotAge support is listed as research ingredients and matching placebo.
Nicolás Cherñavsky
DoNotAge Conference 2026 speaker and lead of an ICR/Unicamp preclinical replication project to which DoNotAge contributed US$25,000. Cherñavsky also co-authored a separate 2025 peer-reviewed acute feasibility/safety study of young-pig-plasma extracellular particles in young rats; that paper is not rejuvenation-efficacy evidence.
Joanna Ward
DoNotAge Conference 2026 speaker and recipient of a DoNotAge.org-BSRA Small Research Grant. The DoNotAge-BSRA award supports Ward's cardiovascular-inflammation research programme; it is distinct from the funding listed for the registered icosapent-ethyl study, whose protocol names Amarin Global and the University of Lincoln.
Sergej M. Ostojic
DoNotAge Scientific Advisory Board member and DoNotAge Conference 2026 speaker. In a DoNotAge video, Ostojic also outlined a planned 24-week older-adult clinical study of the multi-ingredient DoNotAge Performance formulation; the later conference archive described the research as ongoing.
Ciara Gallardo Juan
DoNotAge Conference 2026 speaker. The official conference archive describes DoNotAge support for her PhD research and reports a human exercise study using DoNotAge Pure Quercetin.
Constanza Cortes
DoNotAge Conference 2026 speaker. Conference materials report DoNotAge funding for a prospective aged-mouse PS18-versus-exercise study. Cortes' earlier published muscle-to-brain and skeletal-muscle TFEB studies are separate mechanistic research and should not be represented as DoNotAge-funded PS18 efficacy studies.
Lindsay Bottoms
DoNotAge Conference 2026 speaker and co-presenter of the conference-reported 20-day Pure Quercetin versus placebo study. The related registered study NCT06230861 lists DoNotAge.org as a collaborator.
Jonathan Sinclair
Speaker at DoNotAge Conference 2026; responsible party for ClinicalTrials.gov study NCT06230861, which lists DoNotAge.org as a collaborator.
David Weinkove
Speaker at DoNotAge Conference 2026.
Rebecca Sumner
DoNotAge Conference 2026 speaker. No separate DoNotAge-funded Rebecca Sumner research project was independently identified in the reviewed sources as of October 10, 2026.